Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Xencor Inc (XNCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,971,986
  • Shares Outstanding, K 56,234
  • Annual Sales, $ 35,710 K
  • Annual Income, $ -48,930 K
  • 36-Month Beta 1.60
  • Price/Sales 38.60
  • Price/Cash Flow N/A
  • Price/Book 3.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.53
  • Number of Estimates 3
  • High Estimate -0.48
  • Low Estimate -0.59
  • Prior Year -0.25
  • Growth Rate Est. (year over year) -112.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.69 +15.05%
on 01/28/19
38.50 -5.30%
on 02/05/19
+1.97 (+5.71%)
since 01/15/19
3-Month
31.22 +16.78%
on 12/20/18
42.78 -14.77%
on 11/29/18
-2.50 (-6.42%)
since 11/15/18
52-Week
24.13 +51.10%
on 02/20/18
48.38 -24.64%
on 09/14/18
+11.81 (+47.91%)
since 02/15/18

Most Recent Stories

More News
Xencor to Present at Upcoming Investor Conferences

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today...

XNCR : 36.46 (+3.96%)
Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic disease, and cancer, today...

XNCR : 36.46 (+3.96%)
Report: Developing Opportunities within ONEOK, Alaska Air Group, Comcast, Mack-Cali Realty, Vistra Energy, and Xencor -- Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ONEOK, Inc. (NYSE:OKE), Alaska...

ALK : 66.32 (-0.38%)
CLI : 21.08 (+0.33%)
CMCSA : 37.77 (+1.37%)
VST : 26.51 (+0.76%)
OKE : 67.71 (+1.54%)
XNCR : 36.46 (+3.96%)
Xencor Regains ex-U.S. Commercial Rights to XmAb®13676, CD20 x CD3 Bispecific Antibody

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic disease and cancer, today...

NVS : 89.88 (+0.97%)
XNCR : 36.46 (+3.96%)
Consolidated Research: 2018 Summary Expectations for Xencor, Cyclacel Pharmaceuticals, Amicus Therapeutics, Take-Two Interactive Software, CSG Systems International, and Vonage -- Fundamental Analysis, Key Performance Indications

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Xencor, Inc. (NASDAQ:XNCR),...

FOLD : 11.42 (+1.87%)
VG : 9.98 (+2.89%)
CSGS : 41.25 (-0.48%)
CYCC : 0.79 (-1.25%)
XNCR : 36.46 (+3.96%)
TTWO : 93.30 (+0.02%)
Xencor Presents Initial Data from Phase 1 Study of XmAb®14045 in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced...

XNCR : 36.46 (+3.96%)
Xencor to Present at 30th Annual Piper Jaffray Healthcare Conference

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today...

XNCR : 36.46 (+3.96%)
Xencor: 3Q Earnings Snapshot

MONROVIA, Calif. (AP) _ Xencor Inc. (XNCR) on Monday reported third-quarter net income of $3.2 million, after reporting a loss in the same period a year earlier.

XNCR : 36.46 (+3.96%)
Xencor Reports Third Quarter 2018 Financial Results

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today...

XNCR : 36.46 (+3.96%)
Xencor to Present Initial Data from Phase 1 Study of XmAb®14045 Bispecific Antibody in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced...

XNCR : 36.46 (+3.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators mostly agree with the trend.

See More Share

Trade XNCR with:

Business Summary

Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California.

See More

Key Turning Points

2nd Resistance Point 37.65
1st Resistance Point 37.05
Last Price 36.46
1st Support Level 35.35
2nd Support Level 34.25

See More

52-Week High 48.38
Fibonacci 61.8% 39.12
Last Price 36.46
Fibonacci 50% 36.26
Fibonacci 38.2% 33.39
52-Week Low 24.13

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar